Evidence map›Paper›PMID 42027605›Full record

ArticleThe Lancet regional health. Western Pacific2026

Estimating the economic burden of lower respiratory infections in China from 2020 to 2040: a health-augmented macroeconomic modelling study.

Yue Lin, Hexi Sun, Zhong Cao, Klaus Prettner, Xiaohui Xu, Yuchang Zhou, Peng Yin, David E Bloom, Michael Kuhn, Till Winfried Bärnighausen and 3 more

Abstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yue LinDepartment of Epidemiology, School of Public Health, Shandong University, Jinan, China.
Hexi SunSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhong CaoHeidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany.
Klaus PrettnerDepartment of Economics, Vienna University of Economics and Business, Vienna, Austria.
Xiaohui XuShandong Center for Disease Control and Prevention, Jinan, 250014, China.
Yuchang ZhouBeijing Institute of Geriatrics (P.Z.), Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China.
Peng YinNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
David E BloomHarvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Michael KuhnInternational Institute for Applied Systems Analysis (IIASA), Laxenburg, Austria.
Till Winfried BärnighausenHeidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany.
Bin CaoDepartment of Pulmonary and Critical Care Medicine, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Maigeng ZhouNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Simiao ChenSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lower respiratory infections (LRI) are a major cause of mortality in China, yet there is a striking lack of nationally representative studies and comprehensive evaluations of their long-term economic impact. This study aimed to quantify the long-term economic burden of LRI across China's 31 provinces and regions, and to assess the spatial distribution. Methods: We used an improved health-augmented macroeconomic model (HMM) to estimate the economic burden of LRI in mainland China from 2020 to 2040. The model captures the burden via two channels: (1) the impact of LRI-related mortality and morbidity on labor supply, and (2) the effect of treatment costs on physical capital accumulation. Data were sourced from the China Provincial Burden of Disease Study 2023, the Global Burden of Antimicrobial Resistance Study, and other publicly available literature. Findings: From 2020 to 2040, LRI are projected to impose a cumulative economic loss of CNY 363 billion (95% UI: 216-710). Marked regional disparities were observed: Guangdong incurred the highest absolute burden (CNY 35.6 billion); Guizhou reported the largest economic losses relative to 61‰ GDP; and per capita losses were greatest in Southwest China. Although East and Southwest China bore the largest overall losses, the disease burden was disproportionately concentrated in Southwest China, which accounted for 33.6% of DALYs but only 23.2% of the total economic loss. Middle-income regions experienced the highest total losses (CNY 174 billion), while per capita losses were most pronounced in low-income areas (CNY 426). Notably, the share of treatment-related costs increased with decreasing income levels, ranging from 21% in Northwest China to just 2% in East China. Interpretation: The economic burden of LRI in China is substantial and regionally inequitable, underscoring the substantial economic returns to targeted LRI prevention and control-particularly in under-resourced regions. Far from being a fiscal liability, such investments offer meaningful long-term economic returns and are essential to advancing health and economic equity nationwide. Funding: The study was supported by Horizon Europe (HORIZON-MSCA-2021-SE-01; project number 101086139-PoPMeD-SuSDeV), and Ministry of Science and Technology of the People's Republic of China (project number 2023ZD0506000).

Indexed as

Economic burdenHealth-augmented macroeconomic modellingLower respiratory infections

Identifiers

PMID42027605
PMCPMC13099508

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.